Irinotecanhydrochlorid 3 H2o Bhardwaj

Irinotecan, the active ingredient in Irinotecanhydrochlorid 3 H2O Bhardwaj, is a topoisomerase I inhibitor presented as an injection solution for intravenous use. It is used in the treatment of metastatic colorectal cancer and other advanced solid tumors in adult patients.

GNH USA supplies Irinotecanhydrochlorid 3 H2O Bhardwaj as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is employed in chemotherapy regimens targeting DNA replication in solid tumors.

- Metastatic colorectal cancer: improves progression‑free survival when combined with fluoropyrimidine‑based regimens. - Gastric cancer: used as part of combination therapy for advanced disease. - Pancreatic cancer: incorporated into multi‑agent regimens for unresectable or metastatic disease. - Lung cancer: administered in combination protocols for advanced non‑small cell lung cancer.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea: may occur during or after infusion. - Fatigue: general tiredness reported by many patients.

Serious or Rare Side Effects: - Severe neutropenia with infection: can lead to life‑threatening sepsis. - Febrile neutropenia: fever accompanying low neutrophil counts. - Severe colitis or ileus: intense intestinal inflammation requiring hospitalization.

Before initiating therapy, several safety considerations should be addressed.

- Assess baseline blood counts: monitor CBC before each cycle. - Evaluate liver function: adjust dosing if hepatic impairment is present. - Avoid concurrent strong CYP3A4 inhibitors: may increase irinotecan exposure. - Pregnancy: contraindicated; use effective contraception. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma SN‑38 levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concurrent myelosuppressive agents: increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Anticoagulants (e.g., warfarin): monitor INR as bleeding risk may rise. - Other antineoplastic agents: adjust schedules to manage overlapping toxicities.